ArticleDiscover oncology2026
Lactate metabolism-related interaction perturbation network enables robust stratification of hepatocellular carcinoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Hepatocellular carcinoma (HCC) is characterized by high molecular heterogeneity, posing challenges to precise diagnosis and treatment. Emerging evidence highlights the critical role of lactate metabolism in tumor progression, yet a robust subtype stratification framework based on lactate metabolism (LM)-related interaction perturbation networks remains lacking. Here, we constructed an interaction network using LM-related genes and performed consensus clustering to identify molecular subtypes of HCC. Four distinct subtypes were identified, with Cluster2 exhibiting the worst prognosis and adverse response to immune checkpoint inhibitors (ICIs), validated by independent HCC cohort. Further multi-dimensional characterization revealed that four subtypes differed significantly in clinical features, immune microenvironment, mutational landscape, and intratumoral microbiome composition. Notably, Cluster2 showed the lowest beta-diversity of microbial community and significantly increased relative abundance of genus Streptomyces and Pseudoxanthomonas, which was substantially associated with immune context. To improve prognosis prediction, we identified a 5-gene signature from Cluster2 via least absolute shrinkage and selection operator (LASSO) regression and validated its robustness in predicting survival across multiple HCC cohorts. Our study establishes a robust LM network-driven subtype system for HCC, which not only enhances multidimensional understanding of tumor heterogeneity but also provides a clinically actionable tool for personalized therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.